Navigation Links
First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
Date:10/23/2007

SAN FRANCISCO, Oct. 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) announced preclinical data presented at the 19th annual AACR-NCI-EORTC Symposium show its bis-platinate drug candidates, CT-47613 and CT-47609, kill tumors refractory to currently marketed platinum agents carboplatin, cisplatin and oxaliplatin. These compounds could enter human clinical trials in late 2008.

"Bis-platinates represent a promising new class of platinum-based chemotherapy drugs with a potential broad spectrum of anti-tumor activity. Anti-cancer drugs containing platinum are a cornerstone therapy for a wide range of tumor types including ovarian, testicular, colorectal, head and neck, and lung cancer," said Jack W. Singer, M.D., Chief Medical Officer of CTI. "These bis-platinates, unlike the currently approved platinum compounds, contain two platinum atoms and work by binding to and damaging both strands of DNA making it much more difficult for cancer cells to repair the damage. The preclinical studies presented at this meeting suggest these compounds are substantially more active than the existing monoplatinates -- especially against platinum-resistant tumors. These agents could represent a significant advance in the treatment of a wide variety of cancers."

Novel bisplatinum complexes characterized by an improved in vitro plasma protein binding and in vivo efficacy on xenograft models (Abstract A267)

Scientists from CTI-Europe presented data on two novel bis-platinum complexes, CT-47613 and CT-47609. When tested in animal models of ovarian cancer and colon cancer, the bis-platinates were significantly more potent than the two most commonly used platinum based chemotherapy drugs, carboplatin and cisplatin and oxaliplatin. Importantly these agents demonstrated potent anti-tumor activity in tumors with either acquired or intrinsic resistance to cisplatin or carboplatin, representing the first such class of binuclear platinum based
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The Genesis of Gendicine: The Story Behind the First Gene Therapy
2. Midwest life science stocks sizzle in a tepid first quarter
3. Morgridge Institute for Research seeks first CEO
4. Sonic Foundry reports first cash-positive quarter
5. Angel investors commit $12.7B in first half of `06
6. Aurora team implants Wisconsins first total artificial heart
7. First half of 2006 roundup: Big Pharma trumps biotech
8. GE announces first installation of Discovery VCT
9. GE Healthcare enjoys robust growth in first quarter
10. Madison asks for wireless bids; airport, downtown would be first
11. Tech Digest: Inacom, PKWare at Infosecurity, Firstlogic, Teklynx
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... (PRWEB) December 18, 2014 ... nation’s leading specialty pharmacies, has an expanded team ... clinical pharmacy consultants for prescriber offices in their ... , “We have a variety of Regional ... example, those specializing in hepatitis C help prescribers ...
(Date:12/19/2014)... 18, 2014 Reports from CDC ... States suffer from one or more chronic health conditions ... Medication can address some of these diseases, but may ... many sufferers face. While implanted nerve stimulation devices today ... whole nerve, which can induce side effects. , ...
(Date:12/19/2014)... With only 2 weeks left of ... Sartorius Biohit products . The product specials include Buy ... Pipette Trade-in Program, and free pipette tips. , Sartorius ... the world. They are ideal for lab technicians performing ... ,     Full volume range of 0.1 uL to ...
(Date:12/19/2014)... NEW YORK , Dec. 18, 2014 ... novel therapies for the treatment of chronic pain, announced ... held today. "This was a transformational year ... a promising future for our company," said Sergio ... past year, we have executed on key financial, human ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2
... Help Drive Production Efficiency and Reliability for New Shire ... HON ) today announced it ... research and development capabilities for creating life-saving medications. Shire ... plc, will use several Honeywell solutions - including ...
... the world renowned Japanese Asahi Breweries announced a new partnership, which ... Japan between Mitsui and Asahi. , ... Lexington, KY ... world renowned Japanese Asahi Breweries announced a new partnership, which will ...
... 11 VERIDIAM ( www.veridiam.com ), a major ... and assemblies, custom engineered to meet the needs ... other highly-critical applications, today announced the appointment of ... Gale will head up operations of all Veridiam ...
Cached Biology Technology:Honeywell Technology Selected to Control Manufacturing Processes at Major U.S. Biotech Site 2Honeywell Technology Selected to Control Manufacturing Processes at Major U.S. Biotech Site 3Honeywell Technology Selected to Control Manufacturing Processes at Major U.S. Biotech Site 4Alltech, Mitsui and Asahi Breweries Create New Venture 2Alltech, Mitsui and Asahi Breweries Create New Venture 3Veridiam Appoints Andrew Gale as Chief Executive Officer 2
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... addition of the "Samsung Galaxy S5 - ... report to their offering. ... totally different sensing technology than the iPhone 5S, ... sensor in its product. The Galaxy ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally ... more evident than at international borders. Over the ... scanners have allowed veteran travelers to self process ... Control (APC) Kiosks at an increasing number of ... According to Maxine Most ...
(Date:12/11/2014)... PAUL, Minn. , Dec. 10, 2014 /PRNewswire/ ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ... Adding functional endpoints to toxicology studies ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... in <A HREF=",http://chinese.eurekalert.org/zh/pub_releases/2009-05/sfeb-cai052609.php,">Chinese . Researchers ... expression of a form of cytochrome P-450 (CYP4B1) ... in mice by caffeic acid, an anti-inflammatory antioxidant ... which appear in the June 2009 issue of ...
... a soldier is wounded during combat, surgeons must focus ... Technologies that could improve the repair and regeneration processes ... but they are not being moved quickly enough into ... Georgia Tech Center for Advanced Bioengineering for Soldier Survivability ...
... by millions worldwide to effectively lower blood cholesterol levels, ... (MS) patients treated with high daily dosages. A ... (MNI), McGill University, demonstrates that statin therapy in mice ... system. The findings, published in The American Journal ...
Cached Biology News:Caffeic acid inhibits colitis in a mouse model -- is a drug-metabolizing gene crucial? 2New center at Georgia Tech aims to improve recovery of soldiers with severe injuries 2New center at Georgia Tech aims to improve recovery of soldiers with severe injuries 3One size does not fit all 2
...
...
... ESGRO Complete Derivation Kit is ... ES cells from delayed blastocysts in ... Clonal ... Delayed Blastocyst Incubation Medium Trypsin ...
AedestaTM Animal Organ/Tissue Perfusion Soln....
Biology Products: